Skip to main content
Indian Journal of Surgical Oncology logoLink to Indian Journal of Surgical Oncology
. 2019 Nov 4;11(1):71–74. doi: 10.1007/s13193-019-00985-8

Desmoid-Type Fibromatosis—Clinical Study of an Uncommon Disease

Sreekanth S Kumar 1,, K Rajeevan 2, E Devarajan 3
PMCID: PMC7064704  PMID: 32205974

Abstract

Desmoid-type fibromatosis is an uncommon disease which mimics sarcoma but is more locally aggressive but with less metastatic potential than sarcoma. Diagnosis is difficult and treatment protocols have changed to include more non-surgical options as compared with sarcoma. This is a retrospective study of the clinical presentation, imaging findings, treatment given, and outcomes of pathologically proven desmoid-type fibromatosis patients who presented to government medical college Kozhikode.

Keywords: Desmoid, Fibromatosis, Non-surgical, Tamoxifen

Introduction

Desmoid-type fibromatosis (DF) is an uncommon benign disorder due to proliferation of fibroblasts/myofibroblasts cells that can involve any anatomical location [1]. Unlike soft tissue sarcoma, it lacks metastatic potential but is notorious for local recurrence after excision causing major morbidity for the patient and is classified by the WHO as an intermediate/locally aggressive tumour [2].

Aetiology of DF remains unclear and is most often sporadic though it is associated with Familial Adenomatous Polyposis. The propensity of DF to occur following pregnancy suggests a degree of hormonal sensitivity but direct correlation with oestrogen levels has never been demonstrated [3]. The most common site of sporadic DF is the abdominal wall while the mesentery is the preferred site for FAP-associated DF.

Patients present with a painless mass in the extremity or abdominal wall. Intrabdominal desmoids may rarely present as bowel perforation or obstruction. It usually presents as a single lesion, but recurrences can be multifocal.

MRI is the imaging modality of choice for extremity DF and CT for abdominal variants. The most commonly observed MR imaging appearance of DF is a heterogeneous pattern, with signal iso- to hyperintense to skeletal muscle on T2-weighted images, and isointense to muscle on T1-weighted images [4]. The key diagnostic feature is the hypointense bands on T2W images [5, 6]. On CT scan, DF appears as a soft-tissue mass often sharply marginated in abdominal-wall tumours, or with ill-defined infiltrative margins in extra-abdominal or mesenteric tumours [7]. DF shows variable attenuation, similar to or slightly higher than that demonstrated by skeletal muscle, with hyper- and hypoattenuation, probably reflecting collagen and myxoid elements, respectively [8].

Pathology

DF is composed of fibroblasts with no malignant features embedded in a dense collagen matrix with infiltrative growth pattern. Immunostaining is positive for beta-catenin (nuclear) but is not specific for DF [9]. DF are supposed to be hormonally sensitive because young females are most affected. Oestrogen receptor positivity by immunohistochemistry has varied from 0 to 54% in various series [1012]. However the response of these tumours to anti-oestrogens is not related to receptor status [13].

Treatment

Surgical excision with wide margins used to be the standard of care mimicking soft tissue sarcoma treatment guidelines. However achieving surgical margins are more difficult than in sarcoma because of infiltrative growth pattern. Also wider surgical margins do not correlate with lesser recurrence, and the resultant morbidity may not justify performing extensive surgery [1417]. Observational and medical management of fibromatosis has been described by several authors with surgery reserved for those with disease progression. Medical treatments used by various investigators include anti oestrogen therapy—tamoxifen in doses from 20 mg/day [18] to 160 mg/day [19]; toremifene 200 mg/day [18], progesterone 100 mg/day, cytotoxic chemotherapy–doxorubicin with dacarbazine or doxorubicin with cyclophosphamide and vincristine or methotrexate with a vinca alkaloid [20, 21]—disease stabilization was reported in at least 50% of these patients with 20–28% of patients showing regression of their disease [22, 23].

The following are the challenges in the management of DF:

  1. Establishing a diagnosis as the histologic appearance of bland fibroblasts with normal mitotic activity makes distinction from normal connective tissue difficult.

  2. Given its deep seated location obtaining biopsies is tricky in case of abdominal fibromatosis

  3. Lack of a characteristic immunohistochemical profile makes diagnosis difficult

  4. Imaging characteristics resemble normal connective tissue or sarcoma

  5. Achieving margins during surgery is difficult due to the creeping nature of infiltration

  6. Monitoring patients on non-surgical treatment plan

  7. Deciding between the various medical options available

Study

There were 11 cases of biopsy proven desmoid-type fibromatosis (DF) that reported to our hospital from July 2015 to July 2018. Of these, 10 were females and 1 was male. Follow-up varied from 4 to 1 year with mean follow-up of 24 months. The anatomic distribution of these lesions is given in Table 1.

Table 1.

Anatomic distribution of these lesions

Patient no Sex Age Location of tumour
1 F 34 Right subscapular area
2 F 34 Right calf
3 F 40 Left cubital fossa
4 F 36 Parietal abdominal wall
5 M 14 Suprapubic area
6 F 18 Suprapubic area
7 F 20 Suprapubic area
8 F 41 Right quadratus lumborum
9 F 18 Forefoot
10 F 60 Shoulder girdle
11 F 70 Right subscapular and axillary area

Clinical Presentation

All patients with lesions of the extremities presented with swelling while pain was the presentation of those with lesions of the parietal wall of abdomen and retroperitoneum. The patient no. 3 presented with a recurrence after excision from another hospital 3 years ago and had pain, swelling, and restriction of movements. Patient 10 was managed non-operatively at a local hospital for 3 years before she presented to us. Two out of 3 lesions in the shoulder girdle had restriction of movements. Nine out of 11 patients were below 45 years of age, and only 2 were elderly. Three of them were below 20 years of age. Both patients who had lower limb disease had deformities of the involved side; 1 was affected with polio, and the other had a congenital deformity.

Imaging Diagnosis

All patients except patient no. 3 and 10 had imaging at our hospital. All extremity lesions underwent MRI while trunk and retroperitoneal lesions underwent CT scan at our centre. When hypointense bands were seen on MRI a high suspicion for desmoid tumour was suggested. Six patients underwent CT scan, and 4 patients had MRI (Table 2).

Table 2.

Radiologic diagnosis

Patient no. Imaging done Was imaging suggestive of DF?
1 CT No
2 MRI Yes
3 NA NA
4 CT No
5 CT Yes
6 CT Yes
7 CT No
8 CT No
9 MRI Yes
10 MRI Yes
11 MRI Yes

Pathologic Diagnosis

Preoperative biopsy was attempted in all cases except patient 3 and 10. Patient 3 had undergone excision from another hospital and her slides could not be reviewed. Patient 10 had biopsy from another hospital and had received medical treatment for the same for 3 years and her slides could not be reviewed. In all except patient 8, biopsy was adequate and representative to reach a final conclusion. Except for patient 11 who underwent an open incisional biopsy for all other patients a core needle biopsy was successful. The pathologic features of DF is fibroblasts with no malignant features embedded in a dense collagen matrix with infiltrative growth pattern (Fig. 1). Immunostaining is positive for beta-catenin (nuclear) but is not specific for DF (Fig. 2). All these patients had bland fibroblasts on histologic examination. Patient 8 underwent excision, and the histology of the resected specimen was consistent with DF.

Fig. 1.

Fig. 1

H&E stain

Fig. 2.

Fig. 2

IHC for B-catenin

Treatment

The treatment given has been summarized in Table 3. Except for patient 1 who was our first patient, our policy has been to offer medical treatment to all patients confirmed to have DF and offer surgery only if disease progresses or becomes symptomatic.

Table 3.

Treatment outcomes

Patient no Treatment Whether negative margins were obtained Recurrence if surgery was performed
1 Right subscapular area Surgery Yes No
2 Right calf Medical NA NA
3 left cubital fossa Surgery No Yes
4 Parietal abdominal wall Medical ➔ surgery Yes No
5 Suprapubic area Medical NA NA
6 Suprapubic area Medical NA NA
7 Suprapubic area Medical NA NA
8 Right quadratus lumborum Surgery No Yes
9 Forefoot Medical NA NA
10 Shoulder girdle Medical NA NA
11 Right subscapular and axillary area Medical NA NA

Patient 1 underwent surgery at our hospital as the primary treatment as imaging revealed a well-defined swelling and excision without morbidity was possible. She is kept on follow-up only. Patient 4 was initially kept on medical management with tamoxifen but complained of increasing pain and size of the swelling. She underwent excision of the anterior abdominal wall lesion with mesh reconstruction and received postoperative radiotherapy. Surgical margins of ≥ 1 cm were obtained for both these patients. Patient 3 had undergone excision at another hospital and presented with a recurrence. Her excision was incomplete and on developing recurrence has been put on tamoxifen. Patient 8 underwent excision because biopsy was inconclusive, and imaging was suggestive of sarcoma. We could not achieve negative margins for her because of the lumbar plexus was found coursing through the lesion. She has been put on postoperative tamoxifen. The remaining 7 patients have not undergone excision and are on high dose tamoxifen of 20 mg 5 times a day with 3 monthly follow-ups. Follow-up is with clinical examination and yearly imaging with MRI. None of these patients have had progression of symptoms or size to warrant an excision.

Discussion

DF predominantly affected young females in our series (91% of affected members were female). This is consistent with other series which had 89 [15] to 68% [16] of female patients. Truncal regions were involved in 72% of our patients and extremities in 28%. Peng et al. [16] reported 68% of truncal DF. None of our patient had associated familial adenomatous polyposis. CT scan was suggestive of DF only 2 out of 6 cases. In the remaining cases, CT diagnosis was sarcoma. When MRI was performed, hypointense bands on T2 imaging were present in all the 4 cases. A larger series of 29 cases by Lee et al. had 62% of MRI having the same finding [24]. Deformity may be a risk factor for extremity DF, but the numbers are too small to draw any strong associations. Non-surgical treatment has been successful in keeping the disease at control but requires good communication between doctor and patient to convince patients who might have been advised excision from other centres. Of the 8 patients who were kept on medical treatment only 1 required surgery during follow-up (12.5%). Progression free survival of 50% at 5 years has been shown by retrospective series for asymptomatic patients managed with a frontline conservative wait and watch policy [25]. Close follow-up enables surgical intervention if disease shows progression. We have not tried second line medical management in any of our patients.

Conclusion

DF must be a differential diagnosis to be kept in mind while dealing with soft tissue swellings. Imaging suggestive of diffuse infiltration and clinical finding of restriction of movements in girdle swellings must raise a high suspicion for the same. Proper biopsy and discussion with radiologist is invaluable in reaching a diagnosis. Discussion in tumour board can give the treating doctor confidence in implementing non-surgical treatment line for this disease which will often recur with increasing morbidity if operated upon in the first instance. Surgery can be reserved for painful, progressive lesions, or in non-functional limbs.

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Li M, Cordon-Cardo C, Gerlad WL, et al. Desmoid type fibromatosis is a clonal process. Hum Pathol. 1996;27:9. doi: 10.1016/S0046-8177(96)90221-X. [DOI] [PubMed] [Google Scholar]
  • 2.Fletcher JA, Bridge JA, Hogendorn PCW. WHO classification of tumours of soft tissue and bone. 4. Lyon: IARC; 2013. [Google Scholar]
  • 3.Fiore M, Coppola S, Cannell AJ. Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk. Ann Surg. 2014;259(5):973–978. doi: 10.1097/SLA.0000000000000224. [DOI] [PubMed] [Google Scholar]
  • 4.Dinauer Philip A., Brixey Clark J., Moncur Joel T., Fanburg-Smith Julie C., Murphey Mark D. Pathologic and MR Imaging Features of Benign Fibrous Soft-Tissue Tumors in Adults. RadioGraphics. 2007;27(1):173–187. doi: 10.1148/rg.271065065. [DOI] [PubMed] [Google Scholar]
  • 5.Otero S, Moskovic EC, Strauss DC. Desmoid type fibromatosis. Clin Radiol. 2015;70(9):1038–1045. doi: 10.1016/j.crad.2015.04.015. [DOI] [PubMed] [Google Scholar]
  • 6.Kamali F, Wang WL, Guadanoio BA. MRI may be used as a prognostic indicator in patients with extra-abdominal desmoid tumours. Br J Radiol. 2016;89(1058):20150308. doi: 10.1259/bjr.20150308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Shinagare AB, Ramaiya NH, Jagannathan JP, Krajewski KM, Giardino AA, Butrynski JE, Raut CP. A to Z of desmoid tumors. AJR Am J Roentgenol. 2011;197(6):W1008–W1014. doi: 10.2214/AJR.11.6657. [DOI] [PubMed] [Google Scholar]
  • 8.Murphey MD, Ruble CM, Tyszko SM, Zbojniewicz AM, Potter BK, Miettinen M. From the archives of the AFIP: musculoskeletal fibromatoses: radiologic-pathologic correlation. Radiographics. 2009;29(7):2143–2183. doi: 10.1148/rg.297095138. [DOI] [PubMed] [Google Scholar]
  • 9.Bhattacharya B, Dilworth HP, Iacobuzio-Donahue C. Nuclear beta-catenin expression distinguishes deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. Am J Surg Pathol. 2005;29(5):653–659. doi: 10.1097/01.pas.0000157938.95785.da. [DOI] [PubMed] [Google Scholar]
  • 10.Weiss SW, Langloss JM, Shmookler BM (1986) Estrogen receptor protein in bone and soft tissue tumors. Lab Invest 54(sl) [PubMed]
  • 11.McDougall A, McGarrity G (1979) Extra-abdominal desmoid tumours. J Bone Joint Surg (Br) 61(s.l.) [DOI] [PubMed]
  • 12.Pignatti G, Barbanti-Brodano G, Ferrari D. Extraabdominal desmoid tumor. a study of 83 cases. Clin Orthop. 2000;375(s.l.):207–213. doi: 10.1097/00003086-200006000-00025. [DOI] [PubMed] [Google Scholar]
  • 13.Fong Y, Rosen PP, Brennan MF (1993) Multifocal desmoids. Surgery 114(s.l.) [PubMed]
  • 14.The desmoid tumour. Not a benign disease, Posner MC, Shiu MH, Newsome JL (1989) Arch Surg 124(2) [DOI] [PubMed]
  • 15.Huang K, Fu H, Shi Y. Prognostic factors for desmoid tumours: a 20 year experience of a single institution. J Surg Oncol. 2009;100(7):563–569. doi: 10.1002/jso.21384. [DOI] [PubMed] [Google Scholar]
  • 16.Peng PD, Hyder O, Mavros MN. Management and recurrence patterns of desmoid tumors: a multi institutional analysis of 211 patients. Ann Surg Oncol. 2012;19(13):4036–4042. doi: 10.1245/s10434-012-2634-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Mullen JT, Delaney TF, Kobayashi WK. Desmoid tumour: analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol. 2012;19(13):4028–4035. doi: 10.1245/s10434-012-2638-2. [DOI] [PubMed] [Google Scholar]
  • 18.Desmoid tumours treated with triphenylethylenes, Brooks MD, Ebbs SR, Colletta AA (1992) Eur J Cancer 28A [DOI] [PubMed]
  • 19.Izes JK, Zinman LN, Larsen CR. Regression of large pelvic desmoid tumour by tamoxifen and sulindac. Urology. 1996;47:756–759. doi: 10.1016/S0090-4295(96)00026-X. [DOI] [PubMed] [Google Scholar]
  • 20.Pilz T, Pilgrim TB, Bisogno G (1999) Chemotherapy in fibromatoses of childhood and adolescence: results from the cooperative soft tissue sarcoma study (CWS) and the Italian Cooperative study group(ICG-AIEOP). Klin Padiatr 211 [DOI] [PubMed]
  • 21.Weiss AJ, Lackman RD. low dose chemotherapy of desmoid tumours. Cancer. 1989;64:1192–1194. doi: 10.1002/1097-0142(19890915)64:6<1192::AID-CNCR2820640605>3.0.CO;2-J. [DOI] [PubMed] [Google Scholar]
  • 22.Bonvalot S, Eldweny H, Haddad V. Extra abdominal fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol. 2008;34(4):462–468. doi: 10.1016/j.ejso.2007.06.006. [DOI] [PubMed] [Google Scholar]
  • 23.Nakayama T, Tsuboyama T, Toguchida J (2008) Natural course of desmoid-type fibromatosis. J Orthop Sci 34(4) [DOI] [PubMed]
  • 24.Lee JC, Thomas JM, Phillips S, Fisher C, Moskovic E. Aggressive fibromatosis: MRI features with pathologic correlation. Am J Roentgenol. 2006;186(1):sl. doi: 10.2214/AJR.04.1674. [DOI] [PubMed] [Google Scholar]
  • 25.Kasper B, Baumgarten C, Garcia J, Bonvalot S. An update on the management of sporadic desmoid-type fibromatosis: a european consensus initiative between sarcoma PAtients EuroNet(SPAEN) and European organisation for research and Treatement of Cancer (EORTC)/Soft tissue and bone sarcoma group (STBSG) Ann Oncol. 2017;28(10):s.l.. doi: 10.1093/annonc/mdx323. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Indian Journal of Surgical Oncology are provided here courtesy of Springer

RESOURCES